Private Companies Among Zhejiang Orient Gene Biotech Co., Ltd's (SHSE:688298) Largest Stockholders and Were Hit After Last Week's 7.8% Price Drop

Simply Wall StJan 2 20:25 ET

Chinese Stocks Plunge as Manufacturing Slowdown Dampens Sentiment; Huafu Fashion Down 4%

MT NewswiresJan 2 02:45 ET

Zhejiang Orient Gene Biotech (688298.SH): The "Technology Research and Development Center Construction Project" and the "Marketing Network and Information Management Platform Construction Project" have been extended to December 2025.

Gelonghui, December 27th丨Zhejiang Orient Gene Biotech (688298.SH) announced that the company held the 11th meeting of the 3rd Board of Directors and the 10th meeting of the 3rd Supervisory Board on December 27, 2024, where the proposal on the extension of some fundraising project timelines was approved. The company agreed to extend the expected operational readiness time for the "Technical Research and Development Center Construction Project" and the "Marketing Network and Information Management Platform Construction Project" from the original plan of December 2024 to December 2025. This extension does not change the investment content, total investment amount, or implementation entity of the fundraising projects.

Gelonghui FinanceDec 27, 2024 02:47 ET

Zhejiang Orient Gene Biotech (688298.SH): plans to use no more than 75 million yuan of temporarily idle raised funds for Cash / Money Market management.

On December 27, Ge Long Hui reported that Zhejiang Orient Gene Biotech (688298.SH) announced that the company will temporarily idle raised funds not exceeding 75 million RMB for cash management. Within the specified limit, the funds can be used on a rolling basis, and the usage period is valid for 12 months from the date of approval by the Board of Directors.

Gelonghui FinanceDec 27, 2024 02:46 ET

Zhejiang Orient Gene Biotech Gets US, EU Certifications for Detection Reagents

MT NewswiresDec 20, 2024 04:59 ET

Zhejiang Orient Gene Biotech (688298.SH): obtained the medical instruments registration certificate.

On December 19, Gelonghui reported that Zhejiang Orient Gene Biotech (688298.SH) announced that its wholly-owned subsidiary, USA Hengjian Biotech Co., Ltd., recently obtained the FDA 510(K) license for drug urine cup combined testing reagents (professional/self-testing); Zhejiang Orient Gene's COVID-19/flu A and B antigen triple testing reagents (professional/self-testing) recently obtained the EU IVDR registration certificate. The FDA 510(K) certification obtained by the wholly-owned subsidiary USA Hengjian's drug urine cup combined testing reagents (professional/self-testing) enriches the company's range of drug testing reagents in the USA market and is beneficial.

Gelonghui FinanceDec 19, 2024 03:15 ET